Avenue Therapeutics Q2 net loss narrows to $690,000; revenue drops to no revenue

Reuters2026/08/07 10:03

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Avenue Therapeutics posted a net loss of USD 690,000 for the quarter ended June 30, 2026, swinging from net income of USD 329,000 a year earlier.
No revenue was recorded, versus USD 1.4 million in other revenue in the prior-year quarter tied to the AnnJi license termination and program transfer.
Total operating expenses fell 36% to USD 707,000, driven by a 50% drop in general and administrative costs to USD 460,000.
Operating loss widened to USD 707,000 from operating income of USD 297,000, while interest income slipped 45% to USD 17,000.
ATX-04 Pompe program advanced with a Duke license signed in February 2026; IV tramadol Phase 3 safety study remains subject to financing or partnership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-026372), on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Avenue Therapeutics Q2 net loss narrows to $690,000; revenue drops to no revenue

You may also like

Crypto prices